Allogeneic BMT in a patient with CML and schizophrenia

被引：0
|
作者：
Lightowler, J [1 ]
Feldman, E [1 ]
Ellis, M [1 ]
Littlewood, TJ [1 ]
机构：
[1] Oxford Radcliffe NHS Trust, Oxford, England
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
281
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [41] Severe musculoskeletal pain after cyclosporin A treatment in a patient undergoing allogeneic BMT
    Germing, U
    Sohngen, D
    Heyll, A
    Kobbe, G
    Aul, C
    Schneider, W
    ONCOLOGY REPORTS, 1996, 3 (04) : 775 - 776
  • [42] Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria
    Foster, L. W.
    McLellan, L.
    Rybicki, L.
    Tyler, T.
    Bolwell, B. J.
    BONE MARROW TRANSPLANTATION, 2009, 44 (09) : 607 - 612
  • [43] Ethical reasoning about patient eligibility in allogeneic BMT based on psychosocial criteria
    L W Foster
    L McLellan
    L Rybicki
    T Tyler
    B J Bolwell
    Bone Marrow Transplantation, 2009, 44 : 607 - 612
  • [44] Allogeneic bone marrow transplantation (BMT) without hospital admittance of the patient.
    Diomede, BB
    Pallotta, RS
    Macedo, MCMA
    Saboya, R
    Silva, RL
    Dizik, C
    Loterio, H
    Massumoto, CM
    Rocha, IF
    Chamone, DAF
    Dulley, FL
    BLOOD, 1997, 90 (10) : 4489 - 4489
  • [45] ETHICAL REASONING ABOUT PATIENT ELIGIBILITY IN ALLOGENEIC BMT BASED ON PSYCHOSOCIAL CRITERIA
    Foster, L. W.
    McLellan, L. J.
    Rybicki, L. A.
    Bolwell, B. J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 52 - 52
  • [46] CYTOGENETIC MONITORING IN CML PATIENTS TREATED WITH BMT
    ROSTI, G
    ZACCARIA, A
    TESTONI, N
    CELSO, B
    BANDINI, G
    TASSINARI, A
    ALBERTAZZI, L
    MIGGIANO, C
    TURA, S
    SESSAREGO, M
    MARMONT, AM
    GUALANDI, F
    FRASSONI, F
    GALIMBERTI, M
    FILIPPETTI, DBA
    DIBARTOLOMEO, P
    DIGIROLAMO, G
    PALKA, G
    IZZI, T
    CAPUCCI, A
    HINTERBERGER, W
    POLLAK, C
    HAAS, OA
    MICHAUX, JL
    FERRANT, A
    MECUCCI, C
    VANDENBERGHE, H
    GAHRTON, G
    LINDQUIST, R
    BONE MARROW TRANSPLANTATION, 1989, 4 : 95 - 97
  • [47] ADOPTIVE IMMUNOTHERAPY FOR RECURRENT CML AFTER BMT
    HELG, C
    ROUX, E
    BERIS, P
    CABROL, C
    WACKER, P
    DARBELLAY, R
    WYSS, M
    JEANNET, M
    CHAPUIS, B
    ROOSNEK, E
    BONE MARROW TRANSPLANTATION, 1993, 12 (02) : 125 - 129
  • [48] ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) - IMPROVED RESULTS BY A NEW IMMUNOPROPHYLAXIS
    GRAEVEN, U
    BEELEN, DW
    QUABECK, K
    SAYER, HG
    SCHAEFER, UW
    BLUT, 1988, 57 (04): : 198 - 198
  • [49] Delayed and divergent effects of anti-HY minor histocompatibility antigen reactivity after allogeneic BMT for CML.
    Gratwohl, A
    Hermans, J
    van Biezen, A
    van Houwelingen, H
    Niederwieser, D
    Apperley, J
    BLOOD, 1998, 92 (10) : 320A - 320A
  • [50] Genetic randomization of allogeneic BMT vs drug treatment in chronic myelogenous leukemia:: The German CML study III.
    Hehlmann, R
    Berger, U
    Hochhaus, A
    Reiter, A
    Pfirrmann, M
    Hasford, J
    Heimpel, H
    Hossfeld, DK
    Huber, C
    Kolb, HJ
    Löffler, H
    Pralle, H
    Queisser, W
    Gratwohl, A
    Tobler, A
    BLOOD, 2000, 96 (11) : 141A - 141A
12345